Mycophenolate mofetil: a step forward in the induction treatment of ANCA-associated vasculitis? Comment on the article by Joneset al

التفاصيل البيبلوغرافية
العنوان: Mycophenolate mofetil: a step forward in the induction treatment of ANCA-associated vasculitis? Comment on the article by Joneset al
المؤلفون: Christophe Lelubre, Frédéric Alain Vandergheynst
المصدر: Annals of the Rheumatic Diseases. 79:e100-e100
بيانات النشر: BMJ, 2019.
سنة النشر: 2019
مصطلحات موضوعية: 030203 arthritis & rheumatology, 0301 basic medicine, medicine.medical_specialty, business.industry, Immunology, Absolute risk reduction, ANCA-Associated Vasculitis, medicine.disease, Mycophenolate, Gastroenterology, General Biochemistry, Genetics and Molecular Biology, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Intravenous cyclophosphamide, Rheumatology, Internal medicine, medicine, Immunology and Allergy, Granulomatosis with polyangiitis, business, INDUCTION TREATMENT
الوصف: We have read with interest the results of the MYCYC trial showing that mycophenolate mofetil (MMF) is not inferior to intravenous cyclophosphamide (CYC) in achieving a primary remission in the treatment of ANCA-associated vasculitides (AAV).1 We would like to address several comments. First, in a previous report of the MYCYC trial in 2013, the authors could not establish a non-inferiority of MMF compared with CYC because the lower bound of the 90% CI of the absolute risk difference (RD) crossed the prespecified non-inferiority margin of −12% (MMF: n=46/70 (66%) vs CYC: n=48/70 (69%), RD=−3%, 90% CI −16% to 10%, p=0.06).2 In the current publication, the reported primary remission rates at 6 months are slightly different compared …
تدمد: 1468-2060
0003-4967
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::8c855de9b422577fc744179d04bc05a4Test
https://doi.org/10.1136/annrheumdis-2019-215647Test
حقوق: OPEN
رقم الانضمام: edsair.doi...........8c855de9b422577fc744179d04bc05a4
قاعدة البيانات: OpenAIRE